Growth Metrics

Merck (MRK) Cost of Revenue (2016 - 2026)

Merck has reported Cost of Revenue over the past 18 years, most recently at $4.2 billion for Q1 2026.

  • Quarterly Cost of Revenue rose 22.7% to $4.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $17.2 billion through Mar 2026, up 13.84% year-over-year, with the annual reading at $16.4 billion for FY2025, 7.83% up from the prior year.
  • Cost of Revenue was $4.2 billion for Q1 2026 at Merck, down from $5.6 billion in the prior quarter.
  • Over five years, Cost of Revenue peaked at $5.6 billion in Q4 2025 and troughed at $3.4 billion in Q1 2025.
  • The 5-year median for Cost of Revenue is $3.9 billion (2023), against an average of $4.1 billion.
  • Year-over-year, Cost of Revenue skyrocketed 68.18% in 2022 and then dropped 27.03% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $3.9 billion in 2022, then grew by 0.8% to $3.9 billion in 2023, then fell by 2.15% to $3.8 billion in 2024, then soared by 45.01% to $5.6 billion in 2025, then dropped by 24.43% to $4.2 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's Cost of Revenue are $4.2 billion (Q1 2026), $5.6 billion (Q4 2025), and $3.9 billion (Q3 2025).